Jyoti Nangalia

Jyoti Nangalia studied Medicine at Cambridge University and subsequently trained as a Haematologist. She undertook a PhD at the Cambridge Institute of Medical Research where she developed a passion for genomics. During her PhD, she discovered CALR mutations in the vast majority of patients with JAK2 unmutated myeloproliferative neoplasms (MPN). Testing for CALR mutations in clinical practice is now routine. Utilising cancer genetics to support clinical decision-making is a critical application of genetic sequencing technologies, and following her PhD, she worked on the development of an accurate online personalised predictor of prognosis for patients with blood cancer by integrating clinical and genomic parameters. Her research group focuses on using sequencing technologies to understand exactly when blood cancers originate in patients during their lifetime, their clonal trajectories and the landscape of selection on driver mutations in blood. Her team studies somatic mutagenesis and epigenetic readouts to understand the changes in blood over lifespan, from development to ageing, pre malignancy to cancer.

She is currently a Principal Investigator at the Cambridge Stem Cell Institute and a Cancer Research UK Clinician Scientist at the Wellcome Sanger Institute with a group shared between both institutes. She is a Consultant Haematologist and treats patients with MPN. She is a member of the MPN clinical study subgroup of the National Cancer Research Institute and has contributed to the writing of national guidelines for MPN in the UK and analysis of MPN clinical trials.